Product Images Duloxetine Delayed-release

This is a graph showing the proportion of patients with relapse based on the treatment received (placebo or duloxetine) and the time elapsed from randomization to relapse (in days). The y-axis ranges from 0 to 1.0, with increments of 0.2, while the x-axis ranges from 0 to 250 days, with increments of 50.*

This text represents a chart showing the percentage of patients improved using a placebo and DUL 60/120 mg once daily for pain management. The x-axis of the chart indicates the percentage of improvement in pain from baseline, while the y-axis represents the frequency of patients. The chart shows that a higher percentage of patients on DUL 60/120 mg once daily experienced an improvement in pain compared to those on the placebo.*

This is a chart that displays the percentage of patients who have improved from their baseline pain levels through a placebo or 60mg of DUL taken once daily. The percentage of improvement ranges from 210% to 280%.*

The text describes a chart showing the percentage of patients improved based on the level of pain (BOCF) from a baseline measurement. The data is represented for two groups: Placebo and DULBO/120 mg taken once daily. The chart displays the percentage of patients improved from 0% to 100%, with increments of 10%. The highest improvement for both groups is above 80%, with DULBO/120 mg showing the greatest level of improvement.*

This is a description of a medication called Duloxetine. It is a delayed-release capsule in a 20mg dosage form. Each capsule contains 22 Sme of Duloxetine Hydrochloride equivalent to 20mg of Duloxetine. The packaging size and expiry date are not provided in the text. The medication is manufactured by Breckenridge Pharmaceuticals, Inc. in Boca Raton, FL. The text includes some dosage instructions for the medication, but they are not legible due to errors.*